Novo Nordisk Sues Eli Lilly Over Alleged Deceptive Advertising
In a high-stakes legal move, Danish pharmaceutical giant Novo Nordisk (NYSE: NVO) filed a lawsuit against Eli Lilly (NYSE: LLY), accusing the latter of misleading advertising regarding its GLP-1 weight-loss drug Zepbound. The dispute centers on claims in Eli Lilly's TV ads that suggest Zepbound is more effective than Novo’s Wegovy, citing an outdated study showing 50 pounds lost versus 33 for Wegovy. Novo Nordisk argues the comparison is misleading because a higher-dose version of Wegovy was approved and launched later. Recent data shows this new dose results in average weight loss of 47 pounds — closer to Zepbound’s performance. The lawsuit seeks an injunction against Eli Lilly's ads, corrective advertising, and unspecified damages for lost profits. The GLP-1 drug market is booming, with Tirzepatide-based drugs like Mounjaro (Lilly) and Ozempic/Wegovy (Novo Nordisk) dominating. The obesity medicine sector reached $66 billion in 2025 and could hit $120 billion by 2030.
Topics: GLP-1 Drugs Investor Impact Litigation Pharmaceuticals